Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 4,238 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Not applicable Interventional

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

NCT05432479
View directory record Official record
Conditions
Infantile Colic
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
The Archer-Daniels-Midland Company
Industry
Eligibility
3 Weeks to 12 Weeks
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 1:33 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Radicle HealthTM VIP: A Study Assessing the Impact of Health and Wellness Products on Metabolic Health and Related Health Outcomes

NCT07819110
View directory record Official record
Conditions
Metabolic Health
Interventions
Placebo Metabolic Control 1, Active Metabolic Product 1
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

NCT02148796
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Broncho-Vaxom (BV), Placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
6 Months to 18 Months
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Effect of Ramelteon on Smoking Abstinence

NCT02560324
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

NCT01069523
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine Extended Release, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

NCT06727396
View directory record Official record
Conditions
Healthy Subjects
Interventions
CKD-508 Tablet, Placebo Tablet
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

NCT04534114
View directory record Official record
Conditions
End Stage Renal Disease Requiring Hemodialysis
Interventions
Fesomersen sodium (BAY2976217), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 29, 2026, 1:33 AM EDT
Not listed Phase 3 Interventional

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

NCT02517021
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Santa Monica, California • Whittier, California • Grand Junction, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1b Study of DCR-AUD in Healthy Volunteers

NCT05845398
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
DCR-AUD, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
21 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA on Human Volunteers

NCT01397604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, Squalene
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

NCT02939326
View directory record Official record
Conditions
Glabellar Frown Lines (GL)
Interventions
EB-001 injection, Placebo injection
Drug
Lead sponsor
Bonti, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Fremont, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT03788434
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Brimonidine

NCT03959176
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle GI HealthTM RCA: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health and Related Health Outcomes

NCT07130058
View directory record Official record
Conditions
GI Health
Interventions
GI Product Form - Control, GI Health Product Form - Active
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

NCT02667236
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution, Vehicle Solution
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 29, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional

Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy

NCT06948058
View directory record Official record
Conditions
Smoking Cessation, Obesity and Obesity-related Medical Conditions
Interventions
Electronic Cigarettes (EC), Nicotine replacement therapy (NRT)
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration

NCT01709721
View directory record Official record
Conditions
Management of Chronic Pain
Interventions
Hydromorphone Hydrochloride, Programmable Implantable pump
Drug · Device
Lead sponsor
Piramal Critical Care, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 29, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

Are NSAIDs Effective Enough for Postoperative Pain Control After Functional Endoscopic Sinus Surgery and Septoplasty

NCT03605914
View directory record Official record
Conditions
Pain Control After Functional Endoscopic Sinus Surgery and Septoplasty
Interventions
diclofenac, Norco
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 29, 2026, 1:33 AM EDT
Not listed Phase 2 Interventional Results available

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

NCT00622726
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Conventional Laser for ROP
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Weeks to 22 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
15
States / cities
Pasadena, California • Denver, Colorado • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 29, 2026, 1:33 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

NCT07217301
View directory record Official record
Conditions
IO-resistant sqNSCLC
Interventions
TAK-928, Control Arm
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Jonesboro, Arkansas • Fair Oaks, California • Fountain Valley, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 29, 2026, 1:33 AM EDT